Robert Audet, MD
Interventional Pain Medicine · Weyers Cave, VANPI 1659360311
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional pain medicine clinicians in VA, where the typical reported total is $4,360.
Across 249 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$688
- AbbVie$630
- Boston Scientific$381
- Lundbeck LLC$307
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$290
- Pfizer$286
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,360100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 40 | $688 |
| AbbVie(2 entities) | 37 | $630 |
| Boston Scientific | 18 | $381 |
| Lundbeck LLC | 16 | $307 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $290 |
| Pfizer | 21 | $286 |
| Collegium Pharmaceutical, Inc. | 14 | $273 |
| Daiichi Sankyo Inc. | 9 | $181 |
| Bioventus LLC | 6 | $169 |
| Biohaven Pharmaceuticals, Inc. | 6 | $146 |
| Lilly USA, LLC | 9 | $132 |
| Amgen | 7 | $109 |
| Eisai Inc. | 6 | $94 |
| Biodelivery Sciences International, Inc. | 7 | $92 |
| Medtronic | 7 | $89 |
| Redhill Biopharma Inc. | 5 | $79 |
| Teva Pharmaceuticals USA, Inc. | 5 | $77 |
| Tersera Therapeutics LLC | 2 | $41 |
| Vertex | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Kaleo, Inc. | 3 | $34 |
| Novartis | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Tonix Medicines, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Shionogi Inc | 2 | $28 |
| Novo Nordisk | 1 | $27 |
| Avanos Medical | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$125
- UBRELVY$125
- Morphabond ER$100
How this compares
$4,360 in reported general payments places this provider in the 50th percentile of 52 interventional pain medicine providers in Virginia.
See all interventional pain medicine providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 21 | $44,899 |
| Nurtec OdtRimegepant Sulfate | 18 | $28,898 |
| Oxycodone Hcl | 580 | $24,600 |
| Fentanyl | 112 | $21,025 |
| Hydromorphone ErHydromorphone Hcl | 22 | $14,993 |
| LinzessLinaclotide | 15 | $7,625 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 206 | $7,442 |
| Methadone Hcl | 215 | $5,479 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 111 | $3,971 |
| Hydromorphone Hcl | 96 | $3,836 |
| Morphine Sulfate ErMorphine Sulfate | 80 | $3,808 |
| Celecoxib | 45 | $2,911 |
| Gabapentin | 194 | $2,693 |
| Duloxetine Hcl | 87 | $2,031 |
| Ondansetron Hcl | 28 | $1,749 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $286 | $28,89818 claims |
| AbbVieLinzess | $630 | $7,62515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 52 interventional pain medicine providers in Virginia.
Other interventional pain medicine in Weyers Cave
- Ketan PatelHaymarket$133K
- Che TorryNewport News$48K
- Niteesh BhararaReston$25K
- Sassan HassassianManassas$24K
- Raj SurejaNewport News$23K
- Benjamin SeemanRichmond$21K
- Alok GopalWinchester$16K
- Jacob LeeWinchester$14K
- Yaoming GuRichmond$13K
- Rae DavisLansdowne$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.